Rezultati pretrage - Charles Ricordel

  • Prikaz rezultata 1 – 7 od 7
Detaljiziraj rezultate
  1. 1
    Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer

    Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer od Charles Ricordel, Luc Friboulet, Fabio Facchinetti, J-C. Soria

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  2. 2
    High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU

    High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU od Tiphaine Guy, Audrey Créac'hcadec, Charles Ricordel, A. Salé, Baptiste Arnouat, Jean‐Louis Bizec, Marie Langelot, C. Lineau, David Marquette, Françoise Martin, Mathieu Léderlin, S. Jouneau

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  3. 3
    ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment

    ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment od Santiago Ponce, S. Cedrés, Charles Ricordel, Nicolás Isambert, Santiago Viteri, Mercedes Herrera, Alex Martínez‐Martí, Alejandro Navarro, Mathieu Léderlin, Xavier Serres, Jon Zugazagoitia, Sylvia Vetrhus, Magnus Jäderberg, Thomas B. Hansen, Victor Levitsky, Luis Paz‐Ares

    Izdano 2023
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  4. 4
    Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018

    Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018 od Florian Guisier, Catherine Dubos‐Arvis, F. Viñas, H. Doubre, Charles Ricordel, Stanislas Ropert, Henri Janicot, Massimo Bernardi, P. Fournel, R. Lamy, M. Pérol, Jérôme Dauba, Gilles Gonzales, L. Falchero, C. Decroisette, Pascal Assouline, C. Chouaïd, Olivier Bylicki

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  5. 5
    Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma

    Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma od Charlotte Domblides, Karen Leroy, I. Monnet, Julien Mazières, Fabrice Barlési, V. Gounant, Simon Baldacci, B. Mennecier, Anne‐Claire Toffart, Clarisse Audigier-Valette, Ludovic Doucet, Etienne Giroux‐Leprieur, Florian Guisier, Charles Ricordel, Olivier Molinier, M. Pérol, Éric Pichon, G. Robinet, D. Templement-Grangerat, Anne-Marie Ruppert, Nathalie Rabbe, Martine Antoine, Marie Wislez

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  6. 6
    Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018

    Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS... od Olivier Bylicki, Pascale Tomasini, Radj Gervais, Florian Guisier, Isabelle Monnet, Charles Ricordel, Laurence Bigay-Gamé, Margaux Geier, C. Chouaïd, Catherine Daniel, Aurélie Swalduz, Anne‐Claire Toffart, H. Doubre, J.-M. Peloni, Diane Moreau, Fabien Subtil, Jean‐Michel Grellard, Marie Castéra, Bénédicte Clarisse, Pedro-Henrique Martins-Lavinas, C. Decroisette, Laurent Greillier

    Izdano 2023
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  7. 7
    High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

    High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome od Laura Mezquita, Maria Jové, Ernest Nadal, Maria Kfoury, Teresa Morán, Charles Ricordel, Marion Dhooge, Camille Tlemsani, H. Léna, Àlex Teulé, Jose-Valero Álvarez, Judith Raimbourg, Sandrine Hiret, Ludovic Lacroix, Mireia Menéndez, Juana Saldaña, Joan Brunet, P. Lianes, Isabelle Coupier, Édouard Auclin, Gonzalo Recondo, Luc Friboulet, Julien Adam, Emma Green, David Planchard, Thierry Frébourg, Gabriel Capellà, Étienne Rouleau, Conxi Lázaro, Olivier Caron, Benjamin Besse

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: